Category: Technology Licenses
Created On: 2022-04-28
Record Count: 4
- cell therapy
- Drug Discovery
- Stem cells
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 245925
5,869,451 – Peptides and compounds that bind to a receptor
6,121,238 – Peptides and compounds that bind to a receptor
6,251,864 – Peptides and compounds that bind to a receptor
6,083,913 – Peptides and compounds that bind to a thrombopoietin receptor
5,932,546 – Peptides and compounds that bind to the thrombopoietin receptor
Licensed Technology shall mean the technology, know-how, data, information and results relating to the synthesis and characterization of Licensed Compound to be supplied to Licenseel, as referred to Pre-Clinical Evaluation of Tpo Mimetic Peptides Index to Analysis, Biology, Formulation, Pharmacology, Synthesis and DMPK.
Licensed Compound shall mean any composition of matter which uses and/or comprises the AF13948, AF15705, GW350805 and/or GW395058 compounds.
Product shall mean any cellular therapy or gene therapy product developed or manufactured using a Licensed Compound, for which the use of the Licensed Compound would, but for the license granted hereunder, otherwise infringe a Valid Claim of the Licensed Patent Rights.
Thrombopoietin mimetics are drugs that considerably increase platelet production by stimulating the receptor for the hormone thrombopoietin.
The forms of TPO-mimetic is for use as a reagent in producing stem cell therapy products, including CB001.
CB001 is manufactured using one of Licensee's proprietary technologies which allows the isolation, purification and significant expansion of populations of stem cells. Licensee believe this proprietary technology will enable the production of well defined cellular products in therapeutically useful quantities. We are developing CB001 for use in bone marrow and other hematopoietic stem cell transplants. CB001 has entered a Phase I/II clinical trial in older adolescents and adults.
IPSCIO Record ID: 336329
LGD-4665 is a matter of oral thrombopoietin mimetic.
U. S. Patent #7314887 – Thrombopoietin activity modulating compounds and methods
Licensed Compound means any and all thrombopoietin mimetics Controlled by Licensor or its Affiliate during the Term of the Agreement including (a) that certain compound known as LGD-4665 with the molecular structure shown in this Agreement, and all formulations including intravenous formulations), salts, prodrugs, hydrates, solvates, polymorphs, enantiomers and isomers thereof; (b) any back-up compounds to LGD-4665 being developed by Licensor as of the Execution Date, as shown on, or incorporated by reference; and (c) any other thrombopoietin mimetic compounds that are Covered by the Licensed Patents. Notwithstanding the foregoing, for the purpose of this Agreement, an Affiliate shall not include any Third Party which acquires control over Licensor or over which Licensor acquires control after the Execution Date so long as such Third Party does not otherwise become involved in the conduct of Development or Commercialization of the Licensed Compounds.
Thrombopoietin (THPO) also known as megakaryocyte growth and development factor (MGDF) is a protein that in humans is encoded by the THPO gene. Thrombopoietin is a glycoprotein hormone produced by the liver and kidney which regulates the production of platelets.
Severe aplastic anemia is a rare, life-threatening, acquired blood disorder in which a patients bone marrow fails to produce enough red blood cells, white blood cells, and platelets.
IPSCIO Record ID: 383612
Chondrogen shall mean any formulation, dosage form or delivery system that contains culturally expanded, undifferentiated, unmodified human MSCs for local delivery for the Articulating Orthopedic Indication and any Improvements thereto.
Prochymal shall mean any formulation, dosage form or delivery system suitable for Vascular Administration that contains culturally expanded, undifferentiated, unmodified human MSCs, and any Improvements thereto.
Ulcerative Colitis Indication shall mean the use of Prochymal for the treatment or prevention of ulcerative colitis.
Mesenchymal Stem Cells or MSCs shall mean the human formative pluripotential blast cells found inter alia in bone marrow, blood, dermis and periosteum that are capable of differentiating into any of the specific types of mesenchymal or connective tissues.
COPD Indication shall mean the use of Prochymal to treat chronic obstructive pulmonary disease.
Articulating Orthopedic Indication shall mean the use of Chondrogen for preventing or treating diseases, defects or conditions of articulating joints, including cartilage and meniscus repair, osteoarthritis, osteochondral defect repair, and the treatment of acute and chronic orthopedic pain within an articulating joint.
Crohns Indication shall mean the use of Prochymal to treat Crohns disease.
Diabetes Indication shall mean the use of Prochymal for the prevention or treatment of Type I diabetes.
GvHD Indication shall mean the use of Prochymal to treat or prevent graft versus host disease.
Cardiac Indication shall mean the use of Prochymal to treat or prevent acute myocardial infarction.
Pain Therapeutic shall mean use of Chondrogen for the mitigation or relief of orthopedic pain with a Statistically Significant duration of relief of at least one year.
IPSCIO Record ID: 305481
CPS means any system or device for substantially increasing, the number of cells, ex vivo, for human therapeutic uses, that may be configured in different component structures (such as described for the Automated CPS or the Manual CPS).
Licensed Product means the Automated CPS (both the Durables and the Disposables) as used for one or more specific Lymphoid Cell Applications.
Licensor is developing proprietary process technologies and devices for a range of cell therapy applications, including stem cell therapies and gene therapy. The lead product under development, the Licensors Cell Production System (the CPS) consists of a clinical cell culture system with disposable cassettes and reagents for use in the rapidly growing stem cell therapy market.
Licensee, a competitor, along with others, are in advanced stages of development of technologies and products for use in stem cell therapy and other market applications currently being pursued by the Licensor.